Matica Biotechnology
Dr. Song joined the company in April 2021 after 3 years as CEO of ImmuneOncia Therapeutics, an international joint venture developing immuno-oncology therapies.
Dr. Song's background spans more than 20 years of basic research, patient care and biopharmaceutical industry leadership. Prior to ImmuneOncia Therapeutics, she held positions at the U.S. National Institutes of Health, Samsung, and Sanofi.
This person is not in any offices